The Claim

Semaglutide 2.4 mg administered subcutaneously once weekly causes a reduction in liver fibrosis without worsening steatohepatitis in approximately 36.8% of patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage 2 or 3, compared to 22.4% with placebo, representing an absolute difference of 14.4 percentage points (95% CI, 7.5 to 21.3; P<0.001) at 72 weeks.

Source: Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
88score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

A weekly injection of semaglutide (2.4 mg) reduces liver scarring in about 37% of people with MASH and moderate liver fibrosis, compared to 22% receiving a placebo, without worsening liver fat inflammation. The difference of 14.4 percentage points is statistically significant.

See the scientific wording

Once-weekly subcutaneous semaglutide at a dose of 2.4 mg causes a reduction in liver fibrosis without worsening of steatohepatitis in approximately 36.8% of patients with MASH and fibrosis stage 2 or 3, compared to 22.4% with placebo, representing an absolute difference of 14.4 percentage points (95% CI, 7.5 to 21.3; P<0.001) at 72 weeks.

Why this might work

Fat buildup in the liver damages liver cells, causing them to release toxic fats (ceramides) and oxalate. These toxic substances activate immune cells and scar-forming cells, while also harming the blood vessels in the liver. This whole process leads to liver scarring. Semaglutide reduces fat buildup, which stops this chain reaction and allows scarring to heal in some people.

Suggested mechanismbased on 1 study

What the research says

1 study

  1. Study: Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

    The study found that semaglutide helps reduce liver scarring in about 37 out of 100 people with fatty liver disease, compared to about 22 out of 100 who took a placebo, just like the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.